{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:18Z","timestamp":1772166438959,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007917","name":"Agricultural Research Service","doi-asserted-by":"publisher","award":["2090-32000-039-00D"],"award-info":[{"award-number":["2090-32000-039-00D"]}],"id":[{"id":"10.13039\/100007917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000193","name":"International Development Research Centre","doi-asserted-by":"publisher","award":["108525-001"],"award-info":[{"award-number":["108525-001"]}],"id":[{"id":"10.13039\/501100000193","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["i01 BX003312"],"award-info":[{"award-number":["i01 BX003312"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["PR181134"],"award-info":[{"award-number":["PR181134"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI100569"],"award-info":[{"award-number":["AI100569"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI141412"],"award-info":[{"award-number":["R01AI141412"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development","award":["BX002440"],"award-info":[{"award-number":["BX002440"]}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","award":["BX004522"],"award-info":[{"award-number":["BX004522"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"name":"VA Research","award":["14S-RCS001"],"award-info":[{"award-number":["14S-RCS001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The most common apicomplexan parasites causing bovine babesiosis are\n                      <jats:italic>Babesia bovis<\/jats:italic>\n                      and\n                      <jats:italic>B. bigemina<\/jats:italic>\n                      , while\n                      <jats:italic>B. caballi<\/jats:italic>\n                      and\n                      <jats:italic>Theileria equi<\/jats:italic>\n                      are responsible for equine piroplasmosis. Treatment and control of these diseases are usually achieved using potentially toxic chemotherapeutics, such as imidocarb diproprionate, but drug-resistant parasites are emerging, and alternative effective and safer drugs are needed. The endochin-like quinolones (ELQ)-300 and ELQ-316 have been proven to be safe and efficacious against related apicomplexans, such as\n                      <jats:italic>Plasmodium<\/jats:italic>\n                      spp., with ELQ-316 also being effective against\n                      <jats:italic>Babesia microti<\/jats:italic>\n                      , without showing toxicity in mammals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The inhibitory effects of ELQ-300 and ELQ-316 were assessed on the growth of cultured\n                      <jats:italic>B. bovis<\/jats:italic>\n                      ,\n                      <jats:italic>B. bigemina<\/jats:italic>\n                      ,\n                      <jats:italic>B. caballi<\/jats:italic>\n                      and\n                      <jats:italic>T. equi<\/jats:italic>\n                      . The percentage of parasitized erythrocytes was measured by flow cytometry, and the effect of the ELQ compounds on the viability of horse and bovine peripheral blood mononuclear cells (PBMC) was assessed by monitoring cell metabolic activity using a colorimetric assay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We calculated the half maximal inhibitory concentration (IC\n                      <jats:sub>50<\/jats:sub>\n                      ) at 72 h, which ranged from 0.04 to 0.37 nM for ELQ-300, and from 0.002 to 0.1 nM for ELQ-316 among all cultured parasites tested at 72 h. None of the parasites tested were able to replicate in cultures in the presence of ELQ-300 and ELQ-316 at the maximal inhibitory concentration (IC\n                      <jats:sub>100<\/jats:sub>\n                      ), which ranged from 1.3 to 5.7 nM for ELQ-300 and from 1.0 to 6.0 nM for ELQ-316 at 72 h. Neither ELQ-300 nor ELQ-316 altered the viability of equine and bovine PBMC at their IC\n                      <jats:sub>100<\/jats:sub>\n                      in\n                      <jats:italic>in vitro<\/jats:italic>\n                      testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The compounds ELQ-300 and ELQ-316 showed significant inhibitory activity on the main parasites responsible for bovine babesiosis and equine piroplasmosis at doses that are tolerable to host cells. These ELQ drugs may be viable candidates for developing alternative protocols for the treatment of bovine babesiosis and equine piroplasmosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-020-04487-3","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T05:03:49Z","timestamp":1606971829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi"],"prefix":"10.1186","volume":"13","author":[{"given":"Marta G.","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reginaldo G.","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Stone Doggett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Riscoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sovitj","family":"Pou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rozalia A.","family":"Dodean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Nilsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"4487_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0304-4017(94)03107-8","volume":"57","author":"G Uilenberg","year":"1995","unstructured":"Uilenberg G. International collaborative research: Significance of tick-borne hemoparasitic diseases to world animal health. Vet Parasitol. 1995;57:19\u201341.","journal-title":"Vet Parasitol."},{"key":"4487_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ttbdis.2017.08.007","volume":"9","author":"LN Wise","year":"2018","unstructured":"Wise LN, Kappmeyer LS, Silva MG, White SN, Grause JF, Knowles DP. Verification of post-chemotherapeutic clearance of Theileria equi through concordance of nested PCR and immunoblot. Ticks Tick Borne Dis. 2018;9:135\u201340.","journal-title":"Ticks Tick Borne Dis"},{"key":"4487_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.cveq.2014.08.008","volume":"30","author":"LN Wise","year":"2014","unstructured":"Wise LN, Pelzel-McCluskey AM, Mealey RH, Knowles DP. Equine piroplasmosis. Vet Clin N Am-Equine. 2014;30:677\u201393.","journal-title":"Vet Clin N Am-Equine."},{"key":"4487_CR4","doi-asserted-by":"publisher","unstructured":"Florin-Christensen M, Suarez CE, Rodriguez AE, Flores DA, Schnittger L. Vaccines against bovine babesiosis: where we are now and possible roads ahead. Parasitol. 2014;1\u201330. https:\/\/doi.org\/10.1017\/S0031182014000961.","DOI":"10.1017\/S0031182014000961"},{"key":"4487_CR5","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.meegid.2012.07.004","volume":"12","author":"L Schnittger","year":"2012","unstructured":"Schnittger L, Rodriguez AE, Florin-Christensen M, Morrison DA. Babesia: A world emerging. Infect Genetics Evol. 2012;12:1788\u2013809.","journal-title":"Infect Genetics Evol"},{"key":"4487_CR6","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3390\/ijerph16101736","volume":"16","author":"TE Onyiche","year":"2019","unstructured":"Onyiche TE, Suganuma K, Igarashi I, Yokoyama N, Xuan X, Thekisoe O. A review on equine piroplasmosis: epidemiology, vector ecology, risk factors, host immunity, diagnosis and control. Int J Environ Res Public Health. 2019;16:1736.","journal-title":"Int J Environ Res Public Health."},{"key":"4487_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1186\/1471-2164-13-603","volume":"13","author":"LS Kappmeyer","year":"2012","unstructured":"Kappmeyer LS, Thiagarajan M, Herndon DR, Ramsay JD, Caler E, Djikeng A, Gillespie JJ, et al. Comparative genomic analysis and phylogenetic position of Theileria equi. BMC Genomics. 2012;13:603.","journal-title":"BMC Genomics."},{"key":"4487_CR8","first-page":"1000023","volume":"3","author":"A Siddra","year":"2020","unstructured":"Siddra A, Hines JB, Mealey RH, Call DR, Gra\u00e7a T. Exposure to ambient air causes degradation and decreased in vitro potency of buparvaquone and parvaquone. Vet Parasitol X. 2020;3:1000023.","journal-title":"Vet Parasitol X."},{"key":"4487_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.vetpar.2011.05.032","volume":"180","author":"CE Suarez","year":"2011","unstructured":"Suarez CE, Noh S. Emerging perspectives in the research of bovine babesiosis and anaplasmosis. Vet Parasitol. 2011;180:109\u201325.","journal-title":"Vet Parasitol."},{"key":"4487_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0304-4017(86)90151-2","volume":"2","author":"KL Kuttler","year":"1986","unstructured":"Kuttler KL, Johnson LW. Chemoprophylactic activity of imidocarb, diminazene and oxytetracycline against Babesia bovis and B. bigemina. Vet Parasitol. 1986;2:107\u201318.","journal-title":"Vet Parasitol."},{"key":"4487_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.exppara.2017.10.016","volume":"183","author":"M Yamasaki","year":"2017","unstructured":"Yamasaki M, Watanabe N, Idaka N, Yamamori T, Otsuguro KI, Uchida N, et al. Intracellular diminazene aceturate content and adenosine incorporation in diminazene aceturate-resistant Babesia gibsoni isolate in vitro. Exp Parasitol. 2017;183:92\u20138.","journal-title":"Exp Parasitol."},{"key":"4487_CR12","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1128\/AAC.00404-09","volume":"53","author":"ON Schwint","year":"2009","unstructured":"Schwint ON, Ueti MW, Palmer GH, Kappmeyer LS, Hines MT, Cordes RT, et al. Imidocarb dipropionate clears persistent Babesia caballi infection with elimination of transmission potential. Antimicrob Agents Chemother. 2009;53:4327\u201332.","journal-title":"Antimicrob Agents Chemother."},{"key":"4487_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF02356129","volume":"17","author":"I Yeruham","year":"1985","unstructured":"Yeruham I, Pipano E, Davidson M. A field strain of Babesia bovis apparently resistant to amicarbalide isethionate. Trop Anim Health Prod. 1985;17:29\u201330.","journal-title":"Trop Anim Health Prod."},{"key":"4487_CR14","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1128\/AAC.01183-15","volume":"59","author":"GP Miley","year":"2015","unstructured":"Miley GP, Pou S, Winter R, Nilsen A, Li Y, Kelly JX, et al. ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria. Antimicrob Agents Chemother. 2015;59:5555\u201360.","journal-title":"Antimicrob Agents Chemother."},{"key":"4487_CR15","doi-asserted-by":"crossref","first-page":"e02549","DOI":"10.1128\/AAC.02549-19","volume":"64","author":"DA van Schalkwyk","year":"2020","unstructured":"van Schalkwyk DA, Riscoe MK, Pou S, Winter RW, Nilsen A, Duffey M, et al. Novel endochin-like quinolones exhibit potent in vitro activity against Plasmodium knowlesi but do not synergize with proguanil. Antimicrob Agents Chemother. 2020;64:e02549-e2610.","journal-title":"Antimicrob Agents Chemother."},{"key":"4487_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.exppara.2010.10.016","volume":"127","author":"R Winter","year":"2011","unstructured":"Winter R, Kelly JX, Smilkstein MJ, Hinrichs D, Koop DR, Riscoe MK. Optimization of endochin-like quinolones for antimalarial activity. Exp Parasitol. 2011;127:545\u201351.","journal-title":"Exp Parasitol"},{"key":"4487_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.exppara.2007.10.016","volume":"118","author":"RW Winter","year":"2008","unstructured":"Winter RW, Kelly JX, Smilkstein MJ, Dodean R, Hinrichs D, Riscoe MK. Antimalarial quinolones: synthesis, potency, and mechanistic studies. Exp Parasitol. 2008;118:487\u201397.","journal-title":"Exp Parasitol."},{"key":"4487_CR18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1021\/acsinfecdis.7b00062","volume":"3","author":"L Frueh","year":"2017","unstructured":"Frueh L, Li Y, Mather MW, Li Q, Pou S, Nilsen A, et al. Alkoxycarbonate ester prodrugs of preclinical drug candidate ELQ-300 for prophylaxis and treatment of malaria. ACS Infect Dis. 2017;3:728\u201335.","journal-title":"ACS Infect Dis."},{"key":"4487_CR19","doi-asserted-by":"publisher","first-page":"177ra137","DOI":"10.1126\/scitranslmed.3005029","volume":"5","author":"A Nilsen","year":"2013","unstructured":"Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, et al. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci Transl Med. 2013;5:177ra137.","journal-title":"Sci Transl Med."},{"key":"4487_CR20","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.20151519","volume":"213","author":"LA Lawres","year":"2016","unstructured":"Lawres LA, Garg A, Kumar V, Bruzual I, Forquer IP, Renard I, et al. Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone. J Exp Med. 2016;213:1307\u201318.","journal-title":"J Exp Med."},{"key":"4487_CR21","doi-asserted-by":"publisher","first-page":"15936","DOI":"10.1073\/pnas.1208069109","volume":"109","author":"JS Doggett","year":"2012","unstructured":"Doggett JS, Nilsen A, Forquer I, Wegmann KW, Jones-Brando L, Yolken RH, et al. Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc Natl Acad Sci USA. 2012;109:15936\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4487_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1292\/jvms.59.479","volume":"59","author":"A Avarzed","year":"1997","unstructured":"Avarzed A, Igarashi I, Kanemaru T, Hirumi K, Omata Y, Saito A, et al. Improved in vitro cultivation of Babesia caballi. J Vet Med Sci. 1997;59:479\u201381.","journal-title":"J Vet Med Sci"},{"key":"4487_CR23","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1126\/science.7355284","volume":"207","author":"MG Levy","year":"1980","unstructured":"Levy MG, Ristic M. Babesia bovis: continuous cultivation in a microaerophilous stationary phase culture. Science. 1980;207:1218\u201320.","journal-title":"Science"},{"key":"4487_CR24","first-page":"416","volume":"46","author":"CA Vega","year":"1985","unstructured":"Vega CA, Buening GM, Green TJ, Carson CA. In vitro cultivation of Babesia bigemina. Am J Vet Res. 1985;46:416\u201320.","journal-title":"Am J Vet Res."},{"key":"4487_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF00931544","volume":"81","author":"E Zweygarth","year":"1995","unstructured":"Zweygarth E, Just MC, de Waal DT. Continuous in vitro cultivation of erythrocytic stages of Babesia equi. Parasitol Res. 1995;81:355\u20138.","journal-title":"Parasitol Res"},{"key":"4487_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijpddr.2018.04.004","volume":"8","author":"MG Silva","year":"2018","unstructured":"Silva MG, Villarino NF, Knowles DP, Suarez CE. Assessment of Draxxin((R)) (tulathromycin) as an inhibitor of in vitro growth of Babesia bovis, Babesia bigemina and Theileria equi. Int J Parasitol Drugs Drug Resist. 2018;8:265\u201370.","journal-title":"Int J Parasitol Drugs Drug Resist."},{"key":"4487_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0022-1759(91)90122-V","volume":"140","author":"CR Wyatt","year":"1991","unstructured":"Wyatt CR, Goff W, Davis WC. A flow cytometric method for assessing viability of intraerythrocytic hemoparasites. J Immunol Methods. 1991;140:23\u201330.","journal-title":"J Immunol Methods."},{"key":"4487_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3389\/fvets.2020.00096","volume":"7","author":"N Eberhard","year":"2020","unstructured":"Eberhard N, Balmer V, Muller J, Muller N, Winter R, Pou S, et al. Activities of endochin-Like quinolones against in vitro cultured Besnoitia besnoiti tachyzoites. Front Vet Sci. 2020;7:96. https:\/\/doi.org\/10.3389\/fvets.2020.00096.","journal-title":"Front Vet Sci."},{"key":"4487_CR29","doi-asserted-by":"publisher","first-page":"e01866","DOI":"10.1128\/AAC.01866-16","volume":"61","author":"PH Alday","year":"2017","unstructured":"Alday PH, Bruzual I, Nilsen A, Pou S, Winter R, Ben Mamoun C, et al. Genetic evidence for cytochrome b Qi site inhibition by 4(1H)-quinolone-3-diarylethers and antimycin in Toxoplasma gondii. Antimicrob Agents Chemother. 2017;61:e01866-e1916.","journal-title":"Antimicrob Agents Chemother."},{"key":"4487_CR30","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1021\/acsinfecdis.8b00133","volume":"4","author":"EV McConnell","year":"2018","unstructured":"McConnell EV, Bruzual I, Pou S, Winter R, Dodean RA, Smilkstein MJ, et al. Targeted structure-activity analysis of endochin-like quinolones reveals potent Qi and Qo site inhibitors of Toxoplasma gondii and Plasmodium falciparum cytochrome bc1 and identifies ELQ-400 as a remarkably effective compound against acute experimental toxoplasmosis. ACS Infect Dis. 2018;4:1574\u201384.","journal-title":"ACS Infect Dis."},{"key":"4487_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijpddr.2013.01.003","volume":"3","author":"MG Silva","year":"2013","unstructured":"Silva MG, Domingos A, Esteves MA, Cruz ME, Suarez CE. Evaluation of the growth-inhibitory effect of trifluralin analogues on in vitro cultured Babesia bovis parasites. Int J Parasitol Drugs Drug Resist. 2013;3:59\u201368.","journal-title":"Int J Parasitol Drugs Drug Resist."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04487-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-020-04487-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04487-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T13:46:30Z","timestamp":1633355190000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-020-04487-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4487"],"URL":"https:\/\/doi.org\/10.1186\/s13071-020-04487-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-58018\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-58018\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-58018\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-58018\/v4","asserted-by":"object"}]},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"11 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"606"}}